Biogen pharmachem Industries Limited has fulfilled its regulatory compliance obligations by submitting the required quarterly certificate under SEBI regulations for the quarter ended 31st March 2026. The submission was made to BSE Limited on 06.04.2026, demonstrating the company's adherence to mandatory disclosure requirements.

Regulatory Compliance Details

The certificate was submitted pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This regulation mandates companies to provide quarterly certificates regarding the dematerialization of physical share certificates. The submission was made by Director Kelash Bunkar on behalf of Biogen Pharmachem Industries Limited.

Registrar Confirmation

Satellite Corporate Services Private Limited, serving as the company's registrar and share transfer agent, provided the mandatory certificate. The registrar confirmed that during the quarter ended 31st March 2026, no physical share certificates were received for dematerialization. This indicates that shareholders did not convert any physical share certificates to electronic form during this period.

The registrar's certificate specifically confirmed two key compliance aspects:

• The securities are properly listed on stock exchanges
• Standard procedures for certificate verification, mutilation, and record updating are in place

Company Information

Biogen Pharmachem Industries Limited, formerly known as Sun Techno Overseas Limited, operates under CIN L51100GJ1995PLC026702. The company is listed on BSE with scrip code 531752 and security ID BIOGEN. Its registered office is located at Shop No. 8, First Floor, Makers-1 Building, Jawahar Road, Rajkot-360001.

Regulatory Framework

The SEBI regulation requires companies to submit quarterly certificates confirming the proper handling of physical share certificates received for dematerialization. This ensures transparency in the conversion process from physical to electronic shareholding and maintains accurate records with depositories. The certificate was also copied to both National Securities Depository Limited and Central Depository Services (India) Limited as per regulatory requirements.

Biogen Pharmachem Industries Limited has announced the record date for its upcoming bonus share issuance, marking a significant corporate action for existing shareholders. The company has set Friday, May 15, 2026, as the crucial date for determining shareholder eligibility for the proposed bonus equity shares.

Bonus Share Details

The company has proposed issuing bonus shares in an attractive 1:6 ratio, providing substantial value to existing shareholders. Under this arrangement, eligible shareholders will receive 1 new equity share of Rs.1/- each for every 6 existing equity shares of Rs.1/- each that are fully paid up.

Regulatory Compliance

The announcement has been made in compliance with Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has formally communicated this information to BSE Limited, where its shares are listed under scrip code 531752 and scrip ID BIOGEN.

Shareholder Approval Process

The bonus share issuance remains subject to shareholder approval, which the company is obtaining through postal ballot including e-voting facilities. This process ensures compliance with applicable laws and regulations while providing convenient voting options for shareholders.

Corporate Communication

The notification was signed by Kelash Bunkar, Wholetime Director with DIN 10911360, on April 1, 2026. The company has indicated that this information will also be made available on its official website at www.biogenpharma.bar for broader accessibility to stakeholders.

Company Information

Biogen Pharmachem Industries Limited operates from its registered office located at Shop No. 8, First Floor, Makers – 1 Building, Jawahar Road, Rajkot-360001. The company maintains communication through its official email biogenpharmachem@gmail.com and continues to fulfill its disclosure obligations as a listed entity.